Loading…
Disclosed for 94 months, Dec 2018 to Sep 2026.
DSP Healthcare Fund is an active equity fund in the Sectoral / Thematic category from DSP Mutual Fund. In June 2020 it disclosed 25 stocks worth ₹475 Cr, up ₹62.5 Cr from May 2020. Its largest positions were IPCA Laboratories Limited (10.0%), Dr. Reddy's Laboratories Limited (8.4%), JB Chemicals & Pharmaceuticals Limited (8.3%); the ten largest together made up 58.4% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 68.9% of its equity. Cash and debt stood at 7.6%. Compared with May 2020 the fund entered 2 new stocks and exited 2.
Top-10 weight is higher than 79% of peers
Holds more stocks than 8% of peers
Holds more cash than 87% of peers
What these mean: concentration · cash
Every line the fund disclosed, with the change against May 2020. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| IPCA Laboratories Limited | 10.03% | up 1.00 pts | ₹47.6 Cr | up ₹10.4 Cr | Added |
| Dr. Reddy's Laboratories Limited | 8.44% | down 1.04 pts | ₹40.1 Cr | up ₹98 L | Added |
| JB Chemicals & Pharmaceuticals Limited | 8.31% | down 0.92 pts | ₹39.4 Cr | up ₹1.4 Cr | Added |
| Cash, TREPS & receivables | 7.63% | up 1.88 pts | ₹36.2 Cr | up ₹12.5 Cr | Added |
| Divi's Laboratories Limited | 7.39% | down 0.46 pts | ₹35.1 Cr | up ₹2.7 Cr | Added |
| Cipla Limited | 4.64% | up 2.63 pts | ₹22 Cr | up ₹13.7 Cr | Added |
| Aarti Drugs Limited | 4.28% | up 0.51 pts | ₹20.3 Cr | up ₹4.8 Cr | Added |
| Jubilant Pharmova Limited | 4.25% | up 0.95 pts | ₹20.2 Cr | up ₹6.6 Cr | Added |
| Torrent Pharmaceuticals Limited | 3.80% | down 0.56 pts | ₹18 Cr | up ₹7 L | Held |
| Procter & Gamble Health Limited | 3.69% | up 0.50 pts | ₹17.5 Cr | up ₹4.4 Cr | Added |
| Indoco Remedies Limited | 3.56% | down 0.68 pts | ₹16.9 Cr | down ₹59 L | Trimmed |
| Alembic Pharmaceuticals Limited | 3.55% | down 0.35 pts | ₹16.8 Cr | up ₹77 L | Added |
| Abbott Laboratories | 3.24% | down 0.17 pts | ₹15.4 Cr | up ₹1.3 Cr | Added |
| Narayana Hrudayalaya Limited | 3.12% | up 0.43 pts | ₹14.8 Cr | up ₹3.7 Cr | Added |
| Dr. Lal Path Labs Limited | 2.97% | up 0.62 pts | ₹14.1 Cr | up ₹4.4 Cr | Added |
| Abiomed Inc | 2.48% | down 0.19 pts | ₹11.8 Cr | up ₹79 L | Added |
| Unichem Laboratories Limited | 2.42% | up 0.42 pts | ₹11.5 Cr | up ₹3.2 Cr | Added |
| Syngene International Limited | 2.42% | down 0.06 pts | ₹11.5 Cr | up ₹1.3 Cr | Added |
| Intuitive Surgical Inc | 2.26% | up 0.22 pts | ₹10.7 Cr | up ₹2.3 Cr | Added |
| Abbott India Limited | 2.09% | down 0.47 pts | ₹9.9 Cr | down ₹62 L | Trimmed |
| Max Healthcare Institute Limited | 1.99% | up 1.99 pts | ₹9.4 Cr | up ₹9.4 Cr | New |
| ICICI Lombard General Insurance Company Limited | 1.75% | down 0.32 pts | ₹8.3 Cr | down ₹22 L | Trimmed |
| Apollo Hospitals Enterprise Limited | 1.69% | down 0.27 pts | ₹8 Cr | down ₹4 L | Trimmed |
| Ajanta Pharma Limited | 1.63% | down 0.39 pts | ₹7.7 Cr | down ₹58 L | Trimmed |
| Alkem Laboratories Limited | 1.54% | down 0.15 pts | ₹7.3 Cr | up ₹33 L | Added |
| Advaita Allied Health Services Limited | 0.85% | up 0.85 pts | ₹4 Cr | up ₹4 Cr | New |
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Compared with
Since May 2020, the weight rose most in Healthcare Services (+1.8 pts) and Healthcare Equipment & Supplies (+0.3 pts), and fell most in Pharmaceuticals & Biotechnology (−1.5 pts) and Insurance (−0.3 pts).
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
| Sector | Jun 2019 | Dec 2019 | Mar 2020 | May 2020 | Jun 2020 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 70.0% | 67.9% | 67.4% | 70.4% | 68.9% |
| Healthcare Services | 16.2% | 19.1% | 19.0% | 15.0% | 16.8% |
| Pharmaceuticals | 11.7% | 11.3% | 11.6% | 10.3% | 10.0% |
| Healthcare Equipment & Supplies | — | — | — | 2.2% | 2.4% |
| Insurance | 2.1% | 1.6% | 2.1% | 2.2% | 1.9% |
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.
| Jun 2026 |
| ₹3,514 Cr |
| 28 |
| 1 |
| 1 |
| 6.8% |
| 6.8% |
| — |
| May 2026 | ₹3,309 Cr | 28 | 0 | 2 | 6.3% | 6.3% | — |
| Apr 2026 | ₹3,142 Cr | 30 | 0 | 0 | 2.4% | 2.4% | — |
| Mar 2026 | ₹2,892 Cr | 30 | 0 | 0 | 1.5% | 1.5% | — |
| Feb 2026 | ₹3,033 Cr | 30 | 0 | 0 | 1.1% | 1.1% | — |
| Jan 2026 | ₹2,971 Cr | 30 | 0 | 1 | 1.2% | 1.2% | — |
| Dec 2025 | ₹3,114 Cr | 31 | 2 | 0 | 1.0% | 1.0% | — |
| Nov 2025 | ₹3,179 Cr | 29 | 0 | 0 | 2.1% | 2.1% | — |
| Oct 2025 | ₹3,144 Cr | 29 | 0 | 0 | 1.3% | 1.3% | — |
| Sep 2025 | ₹3,074 Cr | 29 | 0 | 0 | 2.0% | 2.0% | — |
| Aug 2025 | ₹3,107 Cr | 29 | 0 | 0 | 2.2% | 2.2% | — |
| Jul 2025 | ₹3,190 Cr | 29 | 0 | 0 | 1.8% | 1.8% | — |
| Jun 2025 | ₹3,057 Cr | 29 | 0 | 1 | 1.1% | 1.1% | — |
| May 2025 | ₹2,961 Cr | 30 | 0 | 0 | 0.4% | 0.4% | — |
| Apr 2025 | ₹2,912 Cr | 30 | 0 | 0 | 0.1% | 0.1% | — |
| Mar 2025 | ₹3,019 Cr | 30 | 0 | 1 | 0.8% | 0.8% | — |
| Feb 2025 | ₹2,951 Cr | 31 | 0 | 0 | 1.7% | 1.7% | — |
| Jan 2025 | ₹3,198 Cr | 31 | 1 | 0 | 0.8% | 0.8% | — |
| Dec 2024 | ₹3,340 Cr | 30 | 1 | 0 | 2.5% | 2.5% | — |
| Nov 2024 | ₹3,249 Cr | 29 | 0 | 0 | 4.8% | 4.8% | — |
| Oct 2024 | ₹3,138 Cr | 29 | 1 | 0 | 2.7% | 2.7% | — |
For any of the 70 earlier months, choose it in “Portfolio as of” at the top of the page.